All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-03-08T16:29:42.000Z

How might the MORPHO trial of gilteritinib impact clinical practice?

Mar 8, 2024
Share:

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, How might the MORPHO trial of gilteritinib impact clinical practice? 

How might the MORPHO trial of gilteritinib impact clinical practice?

Firstly, Craddock provides an overview of the phase III MORPHO trial (NCT02997202), highlighting the impact of measurable residual disease status pre- or posttransplant on survival outcomes; then, he considers the implications on future trials assessing posttransplant maintenance therapies in other patient subgroups. Craddock concludes by emphasizing the need for more randomized trials to optimize transplant outcomes. 

This interview can also be accessed as a podcast here.

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
11 votes - 11 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox